JP2021522229A - 活性を高めるための免疫細胞改変 - Google Patents
活性を高めるための免疫細胞改変 Download PDFInfo
- Publication number
- JP2021522229A JP2021522229A JP2020558896A JP2020558896A JP2021522229A JP 2021522229 A JP2021522229 A JP 2021522229A JP 2020558896 A JP2020558896 A JP 2020558896A JP 2020558896 A JP2020558896 A JP 2020558896A JP 2021522229 A JP2021522229 A JP 2021522229A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cish
- human
- ipsc
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 title description 9
- 230000004048 modification Effects 0.000 title description 2
- 238000012986 modification Methods 0.000 title description 2
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 105
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims abstract description 77
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 39
- 102000004127 Cytokines Human genes 0.000 claims abstract description 29
- 108090000695 Cytokines Proteins 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 26
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 26
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 23
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract description 4
- 244000005700 microbiome Species 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 60
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 108091033409 CRISPR Proteins 0.000 claims description 15
- 230000000638 stimulation Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 10
- 101150043532 CISH gene Proteins 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 238000010354 CRISPR gene editing Methods 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- 108010012154 cytokine inducible SH2-containing protein Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 101150083678 IL2 gene Proteins 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000002062 proliferating effect Effects 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 description 21
- 230000006870 function Effects 0.000 description 9
- 238000002659 cell therapy Methods 0.000 description 7
- 108020005004 Guide RNA Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002414 glycolytic effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 241000382301 Isoplexis Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006539 extracellular acidification Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- 108010057840 ALT-803 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- -1 IFNγ Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940127130 immunocytokine Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
【選択図】図3A
Description
本出願は、2018年5月11日に提出された米国仮出願第62/670,033号の優先権の利益を主張し、その出願は参照により本明細書に組み込まれる。
本発明は、米国立衛生研究所からの助成金番号CA217885およびCA203348を受けて行われた。政府は本発明に特定の権利を有する。
本発明の理解を容易にするため、本明細書で使用されるいくつかの用語および略語を以下のように定義する。
造血とNK分化I:
CISH KO hiPSCを最初に造血前駆細胞に分化させ、次に、NK細胞に分化させた1,2。手短に言えば、6日目にEB内にCD34+細胞が出現した時点で、EBをNK細胞分化に移行させた。手短に言えば、造血前駆細胞を、ダルベッコ改変イーグル培地/Ham F12の2:1混合物(Thermo Fisher Scientific,Waltham,MA,11965092,11765054)、2mMのL−グルタミン(Thermo Fisher Scientific,Waltham,MA,25030081)、1%ペニシリン/ストレプトマイシン(Thermo Fisher Scientific,Waltham,MA,15140122)、25μMのβ−メルカプトエタノール(Thermo Fisher Scientific,Waltham,MA,21985023)、20%熱非働化ヒト血清AB(Corning,NY,U.S.,MT35060CI)、5ng/mLの亜セレン酸ナトリウム(Merck Millipore,Burlington,MA,S5261)、50μMのエタノールアミン(MP Biomedicals,ICN19384590)、20mg/mLのアスコルビン酸(Merck Millipore,Burlington,MA,A4544)、インターロイキン3(IL−3;R&D Systems Minneapolis,MN,203−IL);1週目のみ)、幹細胞因子(SCF;R&D Systems Minneapolis,MN,7466−SC)、インターロイキン15(IL−15;R&D Systems,247−ILB)、Fms様チロシンキナーゼ3リガンド(FLT3L;R&D Systems Minneapolis,MN,308−FK)、およびインターロイキン7(IL−7;R&D Systems Minneapolis,MN,207−IL)を含有するNK細胞分化培地に移した。その後、細胞をこれらの条件に21日間放置し、培地交換を毎週行った。
NK分化培地(NK分化I)で21日の後、浮遊細胞を採取し、間質細胞OP9−DL4(DL4、ノッチリガンドを過剰発現するOP9細胞)を含む6ウェルプレートに14日間移し、フローサイトメトリーで測定してCD45+ CD56+ CD33− CD3−の細胞に発達するまで毎週培地交換を行った。
分化後、照射されたK562−IL21−4−1BBL3,4を使用してNK細胞を増殖させた。手短に言えば、非接着性細胞を除去し、フローサイトメトリーで分析して、CD56+のNK細胞の純度を決定した。その後、これらの細胞を、2:1のaAPC(10,000Gyで照射)とNK細胞を用い、350,000NK細胞/培地1mL(RPMI 1640(Thermo Fisher Scientific,Waltham,MA,11875085)、2mMのL−グルタミン(Thermo Fisher Scientific,Waltham,MA,25030081)、1%ペニシリン/ストレプトマイシン(Thermo Fisher Scientific,Waltham,MA,15140122)、1%非必須アミノ酸(NEAA;Thermo Fisher Scientific,Waltham,MA,11140050)および10%標準FBSまたは10%ヒト血清AB(Thermo Fisher Scientific,Waltham,MA,10100147)を含有)にて刺激した。これには、50〜100U/mLのIL2(Prometheus、65483011607)が添加されていた。
参考文献
1.Knorr,D.A.,Ni,Z.,Hermanson,D.,Hexum,M.K.,Bendzick,L.,Cooper,L.J.,Lee,D.A.& Kaufman,D.S.(2013).Clinical−scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.Stem Cells Transl Med 2,2013.
2.Zhu,H.& Kaufman,D.S.(2019).An improved method to produce clinical scale natural killer cells from human pluripotent stem cells. bioRxiv,2019.
3.Denman,C.J.,Senyukov,V.V.,Somanchi,S.S.,Phatarpekar,P.V.,Kopp,L.M.,Johnson,J.L.,Singh,H.,Hurton,L.,Maiti,S.N.,Huls,M.H.,Champlin,R.E.,Cooper,L.J.& Lee,D.A.(2012).Membrane−bound IL−21 promotes sustained ex vivo proliferation of human natural killer cells.PLoS One 7,2012.
4.Hermanson,D.L.,Bendzick,L.,Pribyl,L.,McCullar,V.,Vogel,R.I.,Miller,J.S.,Geller,M.A.& Kaufman,D.S.(2016).Induced Pluripotent Stem Cell−Derived Natural Killer Cells for Treatment of Ovarian Cancer.Stem Cells 34,2016.
Claims (20)
- ヒトCISH−/−ナチュラルキラー(NK)細胞および薬学的に許容される担体を含む有効量の医薬組成物を、必要とするヒト対象に投与することを含む、ヒト対象の疾患または感染症を治療する方法。
- 前記NK細胞が、人工多能性幹細胞、胚性幹細胞または末梢血細胞に由来する、請求項1に記載の方法。
- 前記CISH−/−NK細胞が前記対象にとって自己由来である、請求項1に記載の方法。
- 前記方法が、有効量の1つ以上のサイトカインを前記対象に投与することをさらに含む、請求項1に記載の方法。
- 前記サイトカインがIL−2および/またはIL−15であり、前記有効量が天然NK細胞による治療で必要とされる有効量より少ない、請求項4に記載の方法。
- 前記疾患が造血器がんまたは固形腫瘍である、請求項1に記載の方法。
- 前記感染症がウイルスまたは微生物によって引き起こされる、請求項1に記載の方法。
- 前記CISH−/−NK細胞がサイトカイン刺激に対して高感受性であり、かつ、天然NK細胞と比較して改善された増殖、抗腫瘍機能および抗ウイルス機能を示す、請求項1に記載の方法。
- ヒトCISH−/−NK細胞および少なくとも1つの薬学的に許容される賦形剤を含む、医薬組成物。
- 前記CISH−/−NK細胞が人工多能性幹細胞、胚性幹細胞または末梢血細胞に由来する、請求項9に記載の医薬組成物。
- 前記CISH−/−NK細胞が人工多能性幹細胞に由来する、請求項9に記載の医薬組成物。
- 前記CISH−/−NK細胞がサイトカイン刺激に対して高感受性であり、かつ、天然NK細胞と比較して改善された増殖、抗腫瘍機能および抗ウイルス機能を示す、請求項9に記載の医薬組成物。
- 前記サイトカイン刺激が、Il−2および/またはIL−15による刺激を含む、請求項12に記載の医薬組成物。
- ヒト人工多能性幹細胞(iPSC)、ヒト胚性幹細胞(ESC)またはヒト末梢血細胞(PBC)からCISH遺伝子を欠失させることと、
インビトロ分化プロトコルを使用して、前記CISH−/−iPSC、ESCまたはPBCからNK細胞を誘導することと、を含む、ヒトCISH−/−NK細胞を作製する方法。 - 前記CISH遺伝子の欠失がCRISPRシステムを使用して達成される、請求項14に記載の方法。
- 前記誘導ステップが、前記CISH−/−iPSC、ESCまたはPBCをCD34+が80%超になるまで分化させ、次にCD45+およびCD56+が80%超になるまで分化させることをさらに含む、請求項14に記載のCISH−/−NK細胞を作製する方法。
- 前記第二の分化がノッチリガンドと接触して起こる、請求項16に記載の方法。
- 前記ノッチリガンドがOP9−DL4細胞によってもたらされる、請求項17に記載の方法。
- ヒトCISH−/−NK細胞を含む細胞培養物。
- 前記CISH−/−NK細胞がサイトカイン刺激に対して高感受性であり、天然NK細胞と比較して改善された増殖、抗腫瘍機能、および抗ウイルス機能を示す、請求項19に記載の細胞培養物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670033P | 2018-05-11 | 2018-05-11 | |
US62/670,033 | 2018-05-11 | ||
PCT/US2019/031979 WO2019217956A1 (en) | 2018-05-11 | 2019-05-13 | Modification of immune cells to increase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021522229A true JP2021522229A (ja) | 2021-08-30 |
JPWO2019217956A5 JPWO2019217956A5 (ja) | 2022-05-25 |
Family
ID=68468422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020558896A Pending JP2021522229A (ja) | 2018-05-11 | 2019-05-13 | 活性を高めるための免疫細胞改変 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210145883A1 (ja) |
EP (1) | EP3790562A4 (ja) |
JP (1) | JP2021522229A (ja) |
KR (1) | KR20210008047A (ja) |
CN (2) | CN117959334A (ja) |
CA (1) | CA3100045A1 (ja) |
WO (1) | WO2019217956A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220143084A1 (en) * | 2019-02-15 | 2022-05-12 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
CN114929250A (zh) * | 2019-12-18 | 2022-08-19 | 爱迪塔斯医药公司 | 用于疗法的经工程化的细胞 |
TW202237826A (zh) | 2020-11-30 | 2022-10-01 | 瑞士商克里斯珀醫療股份公司 | 基因編輯的自然殺手細胞 |
WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017100861A1 (en) * | 2015-12-16 | 2017-06-22 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
WO2017173551A1 (en) * | 2016-04-08 | 2017-10-12 | The Governing Council Of The University Of Toronto | Method for generating progenitor t cells from stem and/or progenitor cells and use of same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ605505A (en) * | 2010-07-13 | 2015-02-27 | Anthrogenesis Corp | Methods of generating natural killer cells |
CN108472314A (zh) * | 2015-07-31 | 2018-08-31 | 明尼苏达大学董事会 | 修饰的细胞和治疗方法 |
-
2019
- 2019-05-13 WO PCT/US2019/031979 patent/WO2019217956A1/en active Application Filing
- 2019-05-13 EP EP19800266.9A patent/EP3790562A4/en active Pending
- 2019-05-13 US US17/047,515 patent/US20210145883A1/en active Pending
- 2019-05-13 KR KR1020207035316A patent/KR20210008047A/ko unknown
- 2019-05-13 CN CN202410133272.2A patent/CN117959334A/zh active Pending
- 2019-05-13 CA CA3100045A patent/CA3100045A1/en active Pending
- 2019-05-13 JP JP2020558896A patent/JP2021522229A/ja active Pending
- 2019-05-13 CN CN201980028855.6A patent/CN112040960B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017100861A1 (en) * | 2015-12-16 | 2017-06-22 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
WO2017173551A1 (en) * | 2016-04-08 | 2017-10-12 | The Governing Council Of The University Of Toronto | Method for generating progenitor t cells from stem and/or progenitor cells and use of same |
Non-Patent Citations (3)
Title |
---|
BLOOD, vol. 128, JPN6023018731, 2016, pages 1336, ISSN: 0005054222 * |
FRONTIERS IN IMMUNOLOGY, vol. 8, JPN6023018729, 2017, pages 631, ISSN: 0005054220 * |
NATURE IMMUNOLOGY, vol. 17, JPN6023018730, 2016, pages 816 - 824, ISSN: 0005054221 * |
Also Published As
Publication number | Publication date |
---|---|
US20210145883A1 (en) | 2021-05-20 |
EP3790562A4 (en) | 2022-01-12 |
WO2019217956A1 (en) | 2019-11-14 |
EP3790562A1 (en) | 2021-03-17 |
CN112040960B (zh) | 2024-02-13 |
CN117959334A (zh) | 2024-05-03 |
KR20210008047A (ko) | 2021-01-20 |
CA3100045A1 (en) | 2019-11-14 |
CN112040960A (zh) | 2020-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021522229A (ja) | 活性を高めるための免疫細胞改変 | |
JP6920644B2 (ja) | 幹細胞の免疫制御作用を調節する方法 | |
Bunnell et al. | New concepts on the immune modulation mediated by mesenchymal stem cells | |
Mehrotra et al. | Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12 | |
Morris et al. | Advances in the understanding of acute graft‐versus‐host disease | |
Dolcetti et al. | Myeloid-derived suppressor cell role in tumor-related inflammation | |
Veiga-Parga et al. | Controlling viral immuno-inflammatory lesions by modulating aryl hydrocarbon receptor signaling | |
Vladimirovna et al. | Mesenchymal stem cells and myeloid derived suppressor cells: common traits in immune regulation | |
JP2014226079A (ja) | Nk細胞の調製方法 | |
Yang et al. | Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy | |
Issaranggun Na Ayuthaya et al. | The immunopathogenic and immunomodulatory effects of interleukin‐12 in periodontal disease | |
JP6164650B2 (ja) | Nk細胞の調製方法 | |
US20200368281A1 (en) | Transforming growth factor beta-resistant natural killer cells | |
Lv et al. | Biology and clinical relevance of follicular cytotoxic T cells | |
Kaur et al. | Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2-/-mice; stark differences between the bone marrow and gingivae | |
Jin et al. | Impact of microRNA‑29b on natural killer cells in T‑cell acute lymphoblastic leukemia Corrigendum in/10.3892/ol. 2020.12273 | |
CA3179176A1 (en) | Stem cell immunomodulatory therapy for covid-19 infection | |
Del Galy et al. | In vivo genome-wide CRISPR screens identify SOCS1 as a major intrinsic checkpoint of CD4+ Th1 cell response | |
EP3893898B1 (en) | Method of treating autoimmune and inflammatory diseases using b cells | |
KR101932840B1 (ko) | 용해성 pd-l1이 처리된 면역조절능을 갖는 골수유래억제세포 및 이의 용도 | |
KR20230153301A (ko) | 이종 면역세포에 대한 화학주성을 유도하는 전능성 줄기세포 유래 면역세포 | |
Shen | Studies on microglia in tumor biology and neurobiology | |
CA3160360A1 (en) | Adoptive cell therapy with zbtb20 suppression | |
Horwitz | Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation | |
Wang | Amino Acid Metabolism in the Inflammatory Niche |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240405 |